This Month in JAAD —February 2021

In  this issue of the Journal of the American Academy of Dermatology, Siscos et al1 examine the risk of discontinuing newer oral anticoagulants (apixaban, rivaroxaban, and dabigatran) before dermatologic surgery and report a low risk of severe thrombotic complications. This has been a controversial t opic, with recent recommendations in the dermatologic literature favoring continuation of anticoagulation but some groups outside of dermatology recommending discontinuing these agents before extensive surgical procedures.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Tags: This month in Source Type: research